What are the key barriers to patient participation in cGvHD clinical trials?
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
What are the key barriers to patient participation in cGvHD clinical trials?
-
ナレーター：
-
著者：
The GvHD Hub spoke with Steven Pavletic, Bethesda, US. We asked, What are the key barriers to patient participation in cGvHD clinical trials?
During this interview, Pavletic discusses key factors that may impact patient participation in chronic graft-versus-host disease (cGvHD) clinical trials, including the practical and emotional demands associated with trial involvement, as well as concerns regarding treatment-emergent adverse events and potential long-term effects of investigational therapies. He highlights the importance of empowering patients and involving them in decisions about their care, with clear communication helping to ensure that patients are well informed and have realistic expectations about trial participation.
Intended for healthcare professionals. This educational resource is independently supported by Sanofi. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Hosted on Acast. See acast.com/privacy for more information.